Anaplastic astrocytoma (AA) and glioblastoma multiforme (GM) both carry a poor prognosis with a median survival time of 24 months and nine months respectively after surgery and radiotherapy."-Treatment with adjuvant chemotherapy has been of additional, albeit moderate, benefit (median survival + 11 months in GM).' 2 4 Recently, attention has been paid to the influence of more extensive surgery on the performance status and survival, although in rather small series. "9 However, performing only limited surgery or no surgery is common, probably out of fear of inflicting unnecessary damage on a patient with a poor short-term prognosis. ' It has also been our policy to There was no evidence of an association between the extent of surgery and age or preoperative neurological function class (table 4), which may be partly due to the fact that the number of patients with extensive surgery (that is, a large resection or a gross total removal) was small (n = 30). Table 5 compares the postoperative and the preoperative neurological function class. The majority of the patients were unchanged (51P%), 290/% showed an improvement and 190°o showed a deterioration. Table 6 shows the relationship between the extent of surgery and the change in the neurological function class. It shows that large resections or gross total removal did not lead to more deterioration than limited surgery. In fact, it shows that with extensive surgery there was often more improvement and frequently less deterioration.
Tumour location
The associations between tumour location, pre-and postoperative function and extent of surgery were analysed by means of crosstabulations. An association was found only between tumour location and extent of sur- Table 7 shows that none of the patients with a gross removal had complications, but there is no apparent trend between the complication rate and the extent of surgery. Conversely, both the one and three month mortality rates were strongly correlated with the extent of surgery: the larger the resection, the smaller the mortality rate. Survival Figure 1 shows that the median survival in AA and GM was respectively eight and four months, with a two year survival of 13% and 0 500 respectively. Figure 2 demonstrates the influence of age on the survival in AA in the < 40, 40-60, and > 60 years of age groups. Age is significantly (p < 0 002) related to prognosis in AA. There was no relationship between age Only six AA patients were treated with extensive surgery. They show a better survival (generalised Wilcoxon test, p = 0 08). In the GM group 24 patients were treated with extensive surgery. Their median survival is four months. For patients treated with limited surgery it is three months. Although the difference between both curves is relatively small, it is statistically significant (generalised Wilcoxon test, p = 0-01). Figure 6 shows a clear difference in survival between non-irradiated and irradiated AA patients with a median survival of respectively three and 12 months. In the GM group the irradiated patients also show a longer survival (median nine months) than the nonirradiated patients (median three months) (fig 7) . Generally, patients with AA had radiotherapy, unless neurological function status made radiotherapy not worthwhile. Thus the division of patients who had radiotherapy or not, was highly biased, and the difference in fig 6 in three month survival between the patients with and without radiotherapy reflects this too. In general, patients with GM did not have radiotherapy. Only twelve patients had radiotherapy in this group for unstated reasons. Table 8 shows the results of the Cox regression analysis. In this multivariate model the effects of age and neurological function class were estimated separately in the AA and the GM group. In the AA group both these factors were significantly associated with the relative death rate, but this was not so for the GM group. Separate estimators for the effect of radiotherapy and the extent of surgery in the AA and GM group were not computed as the number of patients with radiotherapy in the GM group was too small as was the number of patients in, respectively, a large partial resection and gross total removal (table 6). Although one might expect that patients with a poor preoperative neurological function would have more restricted surgery, such a relationship could not be found. Considering our results, one should realise that the majority of the patients (table 5) have a relatively poor preoperative neurological condition. This implies that under these circumstances the grading scale is more sensitive for detecting an improvement rather than deterioration. We do not believe, however, that this would influence the conclusions, as the sensitivity ofthe grading scale bears no relationship to the mode of treatment or any of the other prognostic factors.
There was no correlation between age and extent of surgery nor between histological astrocytoma (AA) and glioblastoma multiforme (GM). The relative death rate of the patients with radiotherapy compared with the group without radiotherapy was 0 40, corrected for the influence of performance status, age, histology and extent of surgery. This means that on average during follow up the risk of dying per unit of time for patients treated with radiotherapy was 0 40 times the same risk for patients with the same characteristics but without radiotherapy. This 0 40 may be partly due to the effect of the radiotherapy and partly to the selection of the patients. Although extensive surgery was performed in only a minority of patients, it proved to be of significant importance as a prognostic factor (p < 0-001). The relative death rate of the patients undergoing more extensive surgery was 0 77, compared to patients undergoing less extensive surgery. Results from other series confirm the influence of the type of surgery on survival.7 16 17 Both age and preoperative performance were 0 2 4 6 8 10 12 14 16 18 20 22 24 Survival (months) 
